Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

by Wei Fang Dai, Jaclyn M. Beca, Ruth Croxford, Wanrudee Isaranawatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Timothy P. Hanna, Kelvin K.W. Chan
Published 2020-04-01

Restructuring Skin Cancer Care in Ontario: A Provincial Plan

by John Milkovich, Tim Hanna, Carolyn Nessim, Teresa M. Petrella, Louis Weatherhead, An-Wen Chan, Jonathan C. Irish, Christian Murray, Grace Bannerman, Claire Holloway, Katharina Forster, Laura Pazzano, Frances C. Wright, the Ontario Skin Cancer Advisory Committee
Published 2021-03-01

Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients

by Sarah Zhou, Daniel Sikorski, Honghao Xu, Andrei Zubarev, May Chergui, François Lagacé, Wilson H. Miller, Margaret Redpath, Stephanie Ghazal, Marcus O. Butler, Teresa M. Petrella, Joël Claveau, Carolyn Nessim, Thomas G. Salopek, Robert Gniadecki, Ivan V. Litvinov
Published 2021-05-01

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

by F Stephen Hodi, Ahmad A Tarhini, John M Kirkwood, Zeynep Eroglu, Henry B Koon, Ni Kang, Vernon K Sondak, Harriet M Kluger, Sandra J Lee, Gary I Cohen, Laura F Hutchins, Donald P Lawrence, Kari L Kendra, David R Minor, Carrie B Lee, Mark R Albertini, Lawrence E Flaherty, Teresa M Petrella
Published 2021-05-01